• Association Study of Gene Polymorphisms With Cardiac Performance

  NCT00730899

  Unknown statusObservationalUpdated Aug 8, 2008
• The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI

  NCT03758248

  Unknown statusObservationalUpdated Dec 8, 2020
• Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events

  NCT06855394

  Active, not recruitingObservationalUpdated Mar 31, 2026
• Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response

  NCT03373552

  Active, not recruitingObservationalUpdated Feb 27, 2025
• Coronary Artery Bypass Grafting: Factors Related to Late Events and Saphenous Graft Patency

  NCT00755248

  Unknown statusObservationalUpdated Sep 18, 2008
• Genetic Determinants of the Coronary Microvascular Obstruction in PCI

  NCT05355532

  CompletedObservationalUpdated Feb 17, 2026

ClinicalTrials.gov ID

NCT06215300

Lead Sponsor

Novosibirsk Scientific Research Institute for Circulatory PathologyOTHER

Overall Status

Unknown status

Study Type

Observational

Enrollment

800Estimated

Last Update Posted

Jan 22, 2024Actual

Start Date

Dec 1, 2022Actual

Primary Completion Date

Nov 1, 2025Estimated

Completion Date

Nov 1, 2025Estimated

Official Title

The Effect of Polymorphism of the GUCY1A3 rs7692387 Gene on Cardiovascular Events After Coronary Artery Bypass Grafting.

Brief Summary

Polymorphism in the GUCY1A3 gene worsens the activity of rCC, causing vasoconstriction and increased platelet aggregation. Studies have shown the association of the GUCY1A3 gene with the risk of coronary heart disease and its complications, with ischemic stroke

Detailed Description

Acetylsalicylic acid is indicated for the prevention of cardiovascular complications after CABG. Class I. The level of evidence A. ECS recommendations, Russian recommendations of cardiologists. However, the main problem of CABG remains thrombotic and thromboembolic complications in the immediate and long-term postoperative period, despite taking acetylsalicylic acid. According to various sources, the resistance to ASA among the population ranges from 5 to 45%. Resistance to ASA is primarily associated with genetic factors: the presence of polymorphisms of genes encoding platelet receptor proteins, and the functional activity of soluble guanylate cyclase (rCC), the synthesis of which is controlled by the GUCY1A3 gene. Studies have shown a link between the GUCY1A3 gene and the risk of coronary heart disease and its complications. The presence of polymorphism in the GUCY1A3 gene significantly worsens the activity of rCC, causing vasoconstriction and increased platelet aggregation. At the same time, acetylsalicylic acid cannot provide effective prevention of thrombotic and thromboembolic complications.

• to Evaluate the Association of GUCY1A3 rs7692387 Gene Polymorphism Carrier on the Development of Cardiovascular Events After Coronary Artery Bypass Grafting

• coronary artery bypass grafting

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Stable ischemic disease 2- 4
• CABG

Exclusion Criteria:

• the need to take any anticoagulants
• thrombocytopenia
• allergy to aspirin.

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Novosibirsk Scientific Research Institute for Circulatory PathologyOTHER

a_kurguzov@meshalkin.ru+79137011917